Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117325 · ClinicalTrials.gov registry record · Phase 3
Study Of Adults And Adolescents With Vasomotor Rhinitis
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 352
- Enrollment target
NCT00117325: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00117325 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 352 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00117325, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 352 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).
Primary Outcome
The daily rTNSS was the average of the AM (morning) and PM (before bed time) rTNSS assessments. Each rTNSS assessment comprised the sum of the three nasal symptom scores for rhinorrhea, nasal congestion and postnasal drip where each symptom was scored on a scale of 0 (no symptoms) to 3 (severe symptoms).. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign
Interventions
- DRUG GW685698X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2005-07-11 |
| Est. Completion | 2006-02-09 |
| Phase | Phase 3 |
What the finished NCT00117325 record still lists
NCT00117325 is an interventional study that assigns participants to a tested intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 1 intervention - of which GW685698X is the first listed.
NCT00117325 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00117325 about?
NCT00117325 is a clinical study titled "Study Of Adults And Adolescents With Vasomotor Rhinitis". The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).
What is the current status of trial NCT00117325?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 352 participants. The study started on 2005-07-11. Estimated completion is 2006-02-09.
What interventions are being tested in trial NCT00117325?
The interventions under investigation include: GW685698X (DRUG).
Who is sponsoring clinical trial NCT00117325?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00117325's enrollment target sits among peer trials
352 1030th of 2000 higher than 968 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05811936 · 352 participants · NA
The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads
- NCT06258941 · 352 participants · Phase 1
Classroom Break, Cognition, and Fitness in Elementary School Children
- NCT06269081 · 352 participants · NA
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
- NCT06337292 · 352 participants · Phase 3
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI